New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2012
16:12 EDTBG, SZYMSolazyme announces Joint Venture Expansion Framework with Bunge unit
Solazyme (SZYM) announced that it has entered into a Joint Venture Expansion Framework Agreement with Bunge Global Innovation, a wholly-owned subsidiary of Bunge Limited (BG). The agreement sets forth the intent of the partners to expand joint venture-owned oil production capacity at Solazyme Bunge Renewable Oils from the current 100,000 metric tons under construction in Brazil to 300,000 metric tons by 2016 at select Bunge owned and operated processing facilities worldwide. Also, the companies intend to expand the portfolio of oils to be produced out of their joint venture facility in Brazil. The expanded field and portfolio of oils would include certain tailored food oils for sale in Brazil, where Bunge is the largest supplier of edible oils through several of its retail brands. The parties intend to work together through joint market development to bring new healthy and nutritious edible oils to the Brazilian market. The parties anticipate negotiation of definitive agreements in the coming months.
News For SZYM;BG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
18:04 EDTSZYMSolazyme files to delay Form 10-K
The company expects to file the subject report on Form 10-K for the fiscal year ended December 31, 2014 on or before the fifteenth calendar day following the due date. The Form 10-K could not be filed by the date required due to unanticipated delays in assembling all information required to complete the audited financial statements that are required to be included in the Form 10-K.
February 26, 2015
16:23 EDTSZYMSolazyme reports Q4 EPS (57c), consensus (47c)
Reports Q4 revenue $14.5M, consensus $17.7M.
February 25, 2015
05:11 EDTSZYMSolazyme receives FDA GRAS No Questions Letter for high oleic algae oil
Solazyme announced that the FDA has issued a favorable response to Solazyme’s notification which concludes that high-oleic algae oil is Generally Recognized as Safe as an ingredient in food products under the intended conditions of use. This No Questions letter will further pave the way for mainstream adoption of superior quality oleic algae oil with unprecedented functional, performance and nutritional benefits, enabling the creation of new products that meet consumer demand for healthy, sustainable ingredients. Solazyme has also received FDA No Questions letters for the whole food ingredient products currently offered within the AlgaVia portfolio, including Whole Algal Protein and Whole Algal Flour.
February 19, 2015
14:34 EDTBGBunge repeats 2017 EPS target about $8.50
Subscribe for More Information
February 17, 2015
07:15 EDTBGConsumer Analyst Group of New York (CAGNY) to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use